Skip to content
Company Analysis

Perspective Therapeutics, Inc. CATX

A comprehensive view of key metrics, scores, and financial health for Perspective Therapeutics, Inc.

Overview of Perspective Therapeutics, Inc.

CATX ASE
Healthcare Medical Devices Small Cap
Perspective Therapeutics, Inc. (CATX), is a Small Cap company, in the Medical Devices industry, last closed at $3.95, about 0.0% overvalued vs fair value, +61.2% 1Y return, ranked 920/1121 in sector.
$3.95
-7.49%
As of April 28, 2026
Previous close • Vol 90d: 123.4%
52-Week Range
Market Cap
$486.50M
Enterprise Value
$463.05M
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Weak
Health
Weak
Efficiency
Fair
Valuation
Weak
Growth
Weak
Profitability
Weak
Health
Weak
Efficiency
Fair
Valuation
Weak
Completeness: 82%
Confidence: 54%
Updated: Mar 8
Top Beats
No strong beats yet

Quick Facts

Website https://www.perspectivetherape...
HQ Seattle, WA
Employees 138
Fiscal year Dec 31

Next Events

Earnings May 12 Estimated

Fair Value Snapshot

Insufficient data
Show more details
  • Revenue data missing or non-positive

Engine Room Money Flow™

Small Cap

Corporate Free Cash Flow - Where revenue goes and how value is created

Flow Steps
Revenue
$0
Gross Profit
$1.4M
-12.2%%
Operating Income
$-66.8M
-63.2%%
Net Income
$-79.3M
-70.5%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Corporate Free Cash Flow

Quality & Reliability Indicators

Cash Conversion Ratio
91.7%
Good

FCF / Net Income - measures how well earnings convert to cash

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
0/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Perspective Therapeutics, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
29
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
23
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 91% Coverage
Trade-Off Triangle Visualization A ternary plot showing CATX's balance between Growth (20.8%), Profitability (29.8%), and Safety (49.4%). Growth 21% Safety 49% Profitability 30%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

21th percentile vs peers
22
Key Signals
EPS Growth YoY 29.2% 52p Revenue CAGR 3Y -9.8% 12p Rev Growth YoY -34.2% 9p TSR -61.3% 20p
Strengths
  • Current Ratio in top 20% of peers (12.68, 98th percentile)
  • Quick Ratio in top 20% of peers (19.36, 99th percentile)
  • Strong liquidity position vs peers
Risks
  • Rev Growth YoY in bottom 20% of peers (-34.2%)

Profitability

31th percentile vs peers
31
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

51th percentile vs peers
51
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Perspective Therapeutics, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
-
- - -
- upside
-
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info